Benzonitrile,2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, monobenzoate
| Title | Journal |
|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. | Journal of molecular modeling 20140401 |
| Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. | Mini reviews in medicinal chemistry 20121101 |
| Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. | Journal of clinical pharmacology 20121001 |
| Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. | Diabetes, obesity & metabolism 20121001 |
| Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. | American journal of physiology. Renal physiology 20121001 |
| Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. | Endocrine 20120601 |
| Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20120501 |
| An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. | Current diabetes reviews 20120501 |
| DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. | Diabetes & metabolism 20120401 |
| Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. | Diabetologia 20120401 |
| Alogliptin benzoate for the treatment of type 2 diabetes. | Expert opinion on pharmacotherapy 20120301 |
| Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. | Diabetes, obesity & metabolism 20111201 |
| Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. | Circulation 20111122 |
| Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. | Diabetes, obesity & metabolism 20111101 |
| Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. | Current medical research and opinion 20111101 |
| EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. | American heart journal 20111001 |
| Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. | Current medical research and opinion 20110901 |
| DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. | Journal of cardiovascular pharmacology 20110801 |
| Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. | Expert opinion on investigational drugs 20110601 |
| An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. | Contemporary clinical trials 20110501 |
| [Alogliptin]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| [A compounding agent of alogliptin and pioglitazone]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. | Diabetes, obesity & metabolism 20110401 |
| Alogliptin for the treatment of type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20110201 |
| Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. | Hospital practice (1995) 20110201 |
| Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. | Biochemical and biophysical research communications 20110107 |
| The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. | European journal of medicinal chemistry 20110101 |
| [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110101 |
| Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. | Vascular pharmacology 20110101 |
| Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications. | Experimental diabetes research 20110101 |
| Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. | PloS one 20110101 |
| DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. | Atherosclerosis 20101201 |
| DPP-4 inhibitors: what may be the clinical differentiators? | Diabetes research and clinical practice 20101101 |
| Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. | Diabetes care 20101101 |
| Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. | Current diabetes reviews 20101101 |
| Alogliptin: a review of its use in the management of type 2 diabetes mellitus. | Drugs 20101022 |
| Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. | Clinical pharmacokinetics 20100901 |
| Managing type 2 diabetes in the primary care setting: beyond glucocentricity. | The American journal of the medical sciences 20100801 |
| Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. | Diabetes, obesity & metabolism 20100301 |
| The physiologic role of incretin hormones: clinical applications. | The Journal of the American Osteopathic Association 20100301 |
| Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. | International journal of clinical pharmacology and therapeutics 20100101 |
| Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. | Vascular health and risk management 20100101 |
| Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. | Diabetes, obesity & metabolism 20091201 |
| Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. | Journal of the American Geriatrics Society 20091101 |
| Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. | Journal of clinical pharmacology 20091001 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Current medical research and opinion 20091001 |
| A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. | Life sciences 20090717 |
| Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. | British journal of pharmacology 20090601 |
| Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. | The Journal of pharmacology and experimental therapeutics 20090501 |
| Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry 20090301 |
| DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. | Advances in therapy 20090301 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. | Diabetes, obesity & metabolism 20090201 |
| Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. | Expert opinion on pharmacotherapy 20090201 |
| The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. | European journal of pharmacology 20090114 |
| Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. | International journal of clinical practice 20090101 |
| New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. | The Diabetes educator 20090101 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. | Diabetes care 20081201 |
| Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. | European journal of pharmacology 20080728 |
| Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. | European journal of pharmacology 20080707 |
| Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. | Current opinion in investigational drugs (London, England : 2000) 20080401 |
| Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. | Clinical therapeutics 20080301 |
| Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. | Clinical therapeutics 20080301 |
| Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. | Current topics in medicinal chemistry 20080101 |
| Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. | Journal of medicinal chemistry 20070517 |